StockData
Biofrontera Inc. logo

Biofrontera Inc. (BFRI) company profile

BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/30
$0.59+0.02 (+4.09%)

Close on Nov 17, 2026Market cap $8.81MP/E –Yield –

About Biofrontera

Pharmaceutical Preparations, SIC 2834

Biofrontera Inc. is a biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical treatments for dermatological conditions, focusing on photodynamic therapy. Its primary product line comprises Ameluz, a prescription drug, and the RhodoLED series of illumination lamps, including BF-RhodoLED and RhodoLED XL. Together, these products are used to treat actinic keratosis, a pre-cancerous skin condition, on the face and scalp. In addition to commercializing these products, the company conducts research and development focused on expanding approved indications. Biofrontera sells its products directly to dermatology offices and groups using a buy-and-bill distribution model.

The company operates primarily in the United States and has an international footprint that includes clinical research activities. As of late 2025, its workforce totals 92 employees, with 75 located in the United States and 19 based in Germany. Biofrontera Inc. maintains its principal executive offices and corporate headquarters in Woburn, Massachusetts.

Summary of the business section of Biofrontera's latest annual report, written by StockData.

Company profile

Company

Legal name
Biofrontera Inc.
Founded
2015
Headquarters
Woburn, MA
Address
120 Presidential Way,, Suite 330 01801
Phone
(781) 245-1325
Employees
92, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum llp, Morristown, New Jersey

Stock & identifiers

Ticker
BFRI
Exchange
Nasdaq
IPO date
Nov 1, 2021
Shares outstanding
15M, Aug 11, 2026
Public float
$6.90M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-20 reverse, Jul 5, 2023
SEC CIK
1858685
CUSIP
09077D209
ISIN
US09077D2099
FIGI
BBG00HTD0PX0
Share class FIGI
BBG00HTD0PY9
LEI
984500444S8BE1EF0179
EIN
47-3765675

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Hermann LuebbertCEO & Chairman, Director352,711
Eugene Frederick LefflerChief Financial Officer206,250
George Patrick JonesChief Commercial Officer–
Beth J. HoffmanDirector–
Kevin Daniel WeberDirector–
Heikki LanckrietDirector–
John J. Borer IiiDirector–
la Huerta Martinez Maria del Pilar deDirector400,000
AG BiofronteraDirector400,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Hermann Luebbert
Chairman and Chief Executive Officer
$489.68K$192.54K$112.63K$73.13K$5.26K$873.23K-33%
Fred Leffler
Chief Financial Officer
$371.00K$89.78K$56.31K$36.56K$551$554.21K-33%
George Jones
Chief Commercial Officer
$96.92K–$60.50K–$213$157.64K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 1, 2021
Offer price
$5.00
Securities offered
3,600,000
Gross proceeds
$18.00M
Exchange
Nasdaq
First trading day
Oct 29, 2021
First-day close
$4.41-11.8%
Lock-up ends (est.)
Apr 27, 2022

“The initial public offering price per unit is $5.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of December 31, 2025, the Company had a total of 92 employees comprised of 75 employees (72 full-time and three part-time) in”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 30, 2026DelistingNotice of delisting from exchange (Form 25)
Jan 7, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 7, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 24, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 23, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 14, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 18, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 27, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 25, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 29, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 20, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 2, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
May 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 2, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 14, 2022ListingRegistration of securities on an exchange (Form 8-A)
Apr 1, 2022Late filingNotification of late filing
Nov 1, 2021IPOInitial public offering priced (424B4 prospectus)
Oct 20, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?